CTLA4 and neoplasm: In particular, the advent of direct tumour targeting mAb like rituximab and trastuzumab, and immunomodulatory mAb which block immune checkpoints such as PD-1, PD-L1 or CTLA-4, have demonstrated impressive clinical efficacy1–5.